Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

Ishikawa, Akira; Kuraoka, Kazuya; Zaitsu, Junichi; Saito, Akihisa; Kuwai, Toshio; Shimizu, Yosuke; Sudo, Takeshi; Tashiro, Hirotaka; Taniyama, Kiyomi; Yasui, Wataru

doi:10.21873/anticanres.14892

Cited by 6 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Annexin A10 was not only associated with the prognosis of cholangiocarcinoma, but also other gastrointestinal and hepatobiliary cancers. Similar to our findings for cholangiocarcinoma, annexin A10 was associated with a poor prognosis for small bowel adenocarcinoma in another study [ 16 ]. On the contrary, annexin A10 was associated with a favorable prognosis for hepatocellular carcinoma [ 11 , 20 ].…”

Section: Discussionsupporting

confidence: 92%

“…The expression of short isoform mRNA of annexin A10, previously mistaken as annexin A10, was associated with favorable prognosis in hepatocellular carcinoma [ 11 ]. Expression of annexin A10 was associated with good prognosis of diffuse-type gastric carcinoma [ 12 , 13 ], but poor prognosis in intestinal-type gastric carcinoma, papillary thyroid cancer, small bowel adenocarcinoma, and serous epithelial ovarian cancer [ 13 – 16 ]. A recent study reported that annexin A10 expression was associated with poor prognosis for the perihilar and distal cholangiocarcinoma but not for the intrahepatic cholangiocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

et al. 2022

View full text Add to dashboard Cite

Background Annexin A10 expression influences the prognosis of several gastrointestinal cancers. We explored the association of annexin A10 expression with the overall survival (OS) of patients who underwent curative surgery for cholangiocarcinoma. Methods Patients who underwent curative surgery for cholangiocarcinoma (except gallbladder cancer) and had pathological stage T1-3N0M0 disease were enrolled. Annexin A10 expression was examined by performing immunohistochemical staining. Patient demographics and survival outcome data were retrieved from medical records. Results In total, 185 patients were enrolled. The primary tumor location was intrahepatic and extrahepatic (including the perihilar region) for 89% and 11% of patients, respectively. Positive annexin A10 staining was detected for 61 (33%) patients and associated with extrahepatic or perihilar cholangiocarcinoma (p = 0.001) and lower histological grade (p < 0.001). Patients with positive annexin A10 staining exhibited significantly poorer survival relative to patients with negative staining results (median OS, 2.5 vs. 4.9 years, p = 0.025). In the multivariate analysis adjusting for age, sex, tumor location, tumor grade, hepatitis infection, and disease stage, positive annexin A10 remained an independent predictor of poor OS (hazard ratio 1.572, p = 0.034). In the subgroup analysis, the association between annexin A10 and prognosis was restricted to intrahepatic cholangiocarcinoma. Among patients with intrahepatic cholangiocarcinoma, patients with positive annexin A10 staining exhibited significantly poorer survival compared with patients with negative annexin A10 staining (median OS, 2.3 vs. 4.9 years, p = 0.008). Conclusion Positive annexin A10 expression was associated with poor prognosis of intrahepatic cholangiocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The Depending on the type of cancer, the overexpression of ANXA10 is associated with a favorable or poor prognosis. 20,21,23,24,30,31 In addition to having prognostic value, ANXA10 can serve as a helpful diagnostic immunomarker in adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. 32 The current study revealed that ANXA10 was significantly overexpressed in UC cases compared with benign cases, particularly in…”

Section: Cytologic Resultsmentioning

confidence: 99%

“…In total, 314 urine cytology samples were collected from patients at Kure-Kyosai Hospital (n = 215) and Hiroshima University Hospital (n = 99) between 2019 and 2022. This study was approved by the Ethics Committee at Kure-Kyosai Hospital (authorization number [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] and Hiroshima University (authorization number E-589). The distribution of urine samples was as follows: voided urine samples (n = 232), bladder washings (n = 10), and ureter or renal pelvic washings (n = 72).…”

Section: Tissue and Cytology Samplesmentioning

confidence: 99%

Dual immunocytochemical staining of annexin A10 and p53 in low‐grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology

Kobayashi

Hayashi

Sentani

et al. 2023

Cancer Cytopathology

View full text Add to dashboard Cite

BackgroundUrothelial carcinoma (UC) is a common type of human cancer and, although urine cytology is a useful method for identifying high‐grade UC (HGUC), its ability to diagnose low‐grade UC (LGUC) is limited. The authors previously reported that annexin A10 (ANXA10) expression was strongly linked to both papillary and early stage LGUC and was inversely correlated with p53 expression in upper tract UC (UTUC) and bladder UC. However, it remains largely unknown whether ANXA10 is useful as a diagnostic marker for urine cytology.MethodsIn this study, the authors used 104 biopsy and 314 urine cytology samples to investigate the efficacy of ANXA10 and p53 expression by immunohistochemistry and immunocytochemistry.ResultsIn immunohistochemistry analysis, expression levels of ANXA10 and p53 were either weak or absent in noncancerous tissues, whereas ANXA10 overexpression was observed patients with LGUC, and strong expression of p53 was identified in patients with HGUC. In immunocytochemistry analysis, sensitivity was not good for the detection of UC, especially UTUC, by cytology alone, but it was improved by combining cytology with ANXA10 and p53 to detect both bladder UC and UTUC. Receiver operating characteristic curve analysis also confirmed the diagnostic superiority of cytology combining ANXA10 and p53 for the detection of all UCs, including both HGUC and LGUC (area under the curve, 0.84).ConclusionsTo the authors’ knowledge, this is the first report that the combination of ANXA10 and p53 has potential application as a diagnostic immunomarker for improving the diagnostic accuracy of urine cytology.

show abstract

“…In relation to its oncopromoter role, ANXA10 has been proposed as a prognostic biomarker and therapeutic target in many tumor types. Of special interest, high ANXA10 expression was reported as an independent poor prognostic biomarker in lung adenocarcinoma ( Yumura et al, 2022 ), glioblastoma multiforme ( Xu et al, 2021 ), serous epithelial ovarian cancer ( Wang et al, 2019 ), pancreatic ductal adenocarcinoma ( Ishikawa et al, 2022b ), small bowel adenocarcinoma ( Ishikawa et al, 2021 ) and papillary thyroid cancer ( Liu X. et al, 2021 ). Interestingly, ANXA10 has also been proposed as a useful and highly specific biomarker for adenocarcinomas of the upper gastrointestinal tract and pancreatobiliary system, and also included in a panel of biomarkers to trace the origin of adenocarcinomas with unknown primary sites ( Lu et al, 2013 ).…”

Section: Annexin A10mentioning

confidence: 99%

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

Prieto-Fernández

Menéndez

Otero-Rosales

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Annexins are an extensive superfamily of structurally related calcium- and phospholipid-binding proteins, largely conserved and widely distributed among species. Twelve human annexins have been identified, referred to as Annexin A1-13 (A12 remains as of yet unassigned), whose genes are spread throughout the genome on eight different chromosomes. According to their distinct tissue distribution and subcellular localization, annexins have been functionally implicated in a variety of biological processes relevant to both physiological and pathological conditions. Dysregulation of annexin expression patterns and functions has been revealed as a common feature in multiple cancers, thereby emerging as potential biomarkers and molecular targets for clinical application. Nevertheless, translation of this knowledge to the clinic requires in-depth functional and mechanistic characterization of dysregulated annexins for each individual cancer type, since each protein exhibits varying expression levels and phenotypic specificity depending on the tumor types. This review specifically and thoroughly examines the current knowledge on annexin dysfunctions in carcinogenesis. Hence, available data on expression levels, mechanism of action and pathophysiological effects of Annexin A1-13 among different cancers will be dissected, also further discussing future perspectives for potential applications as biomarkers for early diagnosis, prognosis and molecular-targeted therapies. Special attention is devoted to head and neck cancers (HNC), a complex and heterogeneous group of aggressive malignancies, often lately diagnosed, with high mortality, and scarce therapeutic options.

show abstract

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

Cited by 6 publications

References 24 publications

Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

Dual immunocytochemical staining of annexin A10 and p53 in low‐grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

Contact Info

Product

Resources

About